Strategic Partnership for Dengue Vaccine Distribution
Dr Reddy's Laboratories announced on September 18 that it has entered into an agreement with Japanese pharmaceutical company Takeda Pharmaceutical to promote and distribute the Qdenga dengue vaccine in India. Following the announcement, Dr Reddy's shares emerged as the top gainer in the Nifty index, rising by more than 2% on the day.
This collaboration facilitates the private-market availability of the vaccine, which has already received regulatory approval in India. The partnership aligns with Dr Reddy's position as the second-largest vaccine player in the country, aiming to address the growing public health burden of dengue.
Regulatory Milestone and Market Timeline
The deal follows the approval of Qdenga by India's drug regulator for use in both pediatric and adult populations, marking it as the first dengue vaccine cleared for the country. According to Dr Reddy's, the vaccine is scheduled to become available in the Indian market in the first half of 2027.
Takeda highlighted the recent recommendation by the Parliamentary Committee on Health to consider the dengue vaccine for inclusion in the Universal Immunization Program. While this reflects growing recognition of dengue as a significant health challenge, the current agreement specifically targets private-market access for eligible individuals.
Product Details and Public Health Context
Qdenga is administered as two 0.5 ml doses, spaced three months apart. A key feature of the vaccine is that it can be administered irrespective of a patient's prior dengue infection status, eliminating the need for pre-vaccination screening.
The introduction of the vaccine comes amid rising global and domestic dengue cases. The World Health Organization reported a record 14.4 million dengue cases and 11,201 deaths globally in 2024. In India, the disease resulted in 232,425 cases and 233 deaths during the same period, underscoring the urgency for preventive measures.
Executive Perspectives
M.V. Ramana, CEO of Global Generics at Dr Reddy's Laboratories, described the introduction of India's first approved dengue vaccine as a significant development for the healthcare landscape. He stated that the collaboration aims to make Qdenga available to eligible individuals to help mitigate the country's dengue burden.
Dr. Mahender Nayak, Head of Intercontinental Markets in Takeda's International Business Unit, emphasized the company's commitment to supporting India's healthcare needs. He noted that the private-market collaboration will enable timely access to the vaccine once it is launched, complementing broader public health discussions regarding universal immunization.